Fineotex Chemical Limited
51.50
INR
-1.27
(-2.41%)
ISIN
INE045J01034
Return %
Stock
S&P 500
1Y
109.56
14.20
3Y
57.18
81.12
5Y
334.05
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Arindam Choudhuri
- Full Time Employees
- 300
- Sector
- Process industries
- Industry
- Industrial specialties
- Address
- Ariisto House Mumbai MA India 400069
- IPO Date
- Jan 15, 2015
- Website
- fineotex.com
- Similar Companies
- Business
- Fineotex Chemical Limited manufactures specialty performance chemicals and enzymes primarily for the textile industry, along with products for cleaning and hygiene, oil and gas, water treatment, construction, leather, paint, agrochemicals, adhesives, and related sectors; its core offerings encompass over 450 items including pre-treatment chemicals, dyeing auxiliaries, printing agents, finishing chemicals such as water and oil repellents and antimicrobials, demulsifiers, corrosion inhibitors, biocides, surfactants, and enzymes supplied to textile processors, garment manufacturers, FMCG companies, oilfield operators, and institutional customers. The company operates state-of-the-art manufacturing plants in Navi Mumbai, Ambernath, and Selangor, Malaysia, with a total capacity of 104,000 metric tons per annum, serving domestic markets in India—which account for about 70% of revenues—and exporting to approximately 70 countries through 102 distributors and 34 technical marketing experts. Founded in 1979 by Surendra Tibrewala and headquartered in Mumbai, India, Fineotex Chemical went public in 2007, listing on the Bombay Stock Exchange in 2011 and the National Stock Exchange in 2015; its Malaysian subsidiary Biotex leads research and development, focusing on high-end textile finishing and paint specialties. Recent developments include raising approximately Rs 3.4 billion through preferential allotments of equity shares and convertible warrants in 2024, with promoters contributing Rs 450 million, followed by successful warrant exercises in November 2025 to fund working capital, inorganic acquisitions, and organic expansions; the company acquired 7 acres of land at Additional Ambernath MIDC for Rs 350 million to build a new 15,000 TPA Phase 1 greenfield plant by mid-2026, commissioned a 100 kWp solar power plant at Ambernath in fiscal 2024, and executed strategic collaborations with Eurodye-CTC of Belgium for specialty chemicals in India, HealthGuard of Australia for global antimicrobial and antiviral solutions via a Malaysian joint venture, and Sasmira Institute in Mumbai for a state-of-the-art R&D center emphasizing sustainable chemistry, alongside a 4:1 bonus issue and 1:2 stock split in late 2025.